| P50 | author | Nazareno Suardi | Q102072899 |
| | Vito Cucchiara | Q114316507 |
| | Shahrokh Shariat | Q7462263 |
| | Francesco Montorsi | Q67191520 |
| | Alberto Briganti | Q67191563 |
| | Andrea Salonia | Q88251851 |
| | Giorgio Gandaglia | Q88616632 |
| | Morgan Rouprêt | Q88883209 |
| P2093 | author name string | Marco Bianchi | |
| P2860 | cites work | Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors | Q27027583 |
| | Cancer statistics, 2014 | Q27861018 |
| | Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function | Q28510096 |
| | Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation | Q30445223 |
| | Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application | Q33382936 |
| | Long-term continence outcomes in men undergoing radical prostatectomy for clinically localized prostate cancer | Q33773296 |
| | Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats | Q34157330 |
| | Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy | Q34285227 |
| | A model for managing erectile dysfunction following prostate cancer treatment | Q34549054 |
| | Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the rat | Q34788065 |
| | Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy | Q35086061 |
| | Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. | Q35148169 |
| | Sildenafil promotes neuroprotection of the pelvic ganglia neurones after bilateral cavernosal nerve resection in the rat. | Q36542393 |
| | The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy | Q36793325 |
| | Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy | Q37225327 |
| | Penile rehabilitation following radical prostatectomy | Q37285735 |
| | Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. | Q37373199 |
| | Use of advanced treatment technologies among men at low risk of dying from prostate cancer. | Q37378693 |
| | Prediction of sexual function after radical prostatectomy. | Q37526780 |
| | Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells | Q37603936 |
| | Targeting cancer with phosphodiesterase inhibitors | Q37650389 |
| | Erectile function rehabilitation in the radical prostatectomy patient | Q37730220 |
| | Penile rehabilitation after prostate cancer treatment: outcomes and practical algorithm | Q37881305 |
| | A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes | Q37968375 |
| | Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function | Q38009182 |
| | Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. | Q38023021 |
| | Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy | Q38042693 |
| | Penile rehabilitation after radical prostatectomy: what the evidence really says | Q38119268 |
| | PDE5 inhibitors: considerations for preference and long-term adherence | Q38122721 |
| | Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). | Q38442239 |
| | Phosphodiesterase inhibitors as anti-cancer drugs | Q40525162 |
| | Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function | Q41865451 |
| | Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy | Q41953078 |
| | Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function | Q42516819 |
| | Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy | Q42662719 |
| | Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. | Q42667696 |
| | Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury. | Q42747753 |
| | Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate | Q43093330 |
| | The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function | Q43297758 |
| | O2-dependent prostanoid synthesis activates functional PGE receptors on corpus cavernosum smooth muscle | Q43675133 |
| | Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: a long-term combined evaluation of surgical outcomes | Q43691773 |
| | A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy | Q43918116 |
| | Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification | Q43919464 |
| | Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates | Q43942810 |
| | Defining the impact of vascular risk factors on erectile function recovery after radical prostatectomy | Q44006112 |
| | Erectile function rehabilitation after radical prostatectomy: practice patterns among AUA members | Q44252106 |
| | Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy | Q44491152 |
| | Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy | Q44721055 |
| | Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery | Q44749931 |
| | Outcome of radical prostatectomy: is it the approach or the surgical expertise? | Q44751870 |
| | Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy | Q45158639 |
| | The hemodynamics of vacuum constriction erections: assessment by color Doppler ultrasound. | Q45954472 |
| | Histological alterations in cavernous tissue after radical prostatectomy. | Q45968091 |
| | Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. | Q46005438 |
| | Men with low preoperative sexual function may benefit from nerve sparing radical prostatectomy. | Q46025964 |
| | Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. | Q46392230 |
| | Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil | Q46595437 |
| | Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. | Q46600601 |
| | Factors predicting continence recovery 1 month after radical prostatectomy: results of a multicenter survey. | Q46642674 |
| | The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate | Q46709754 |
| | Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial | Q46845883 |
| | Subjective characterization of nerve sparing predicts recovery of erectile function after radical prostatectomy: defining the utility of a nerve sparing grading system | Q46859812 |
| | The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function | Q46901062 |
| | Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial | Q46901169 |
| | Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections | Q46947485 |
| | Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection | Q46987652 |
| | Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. | Q46991340 |
| | Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy | Q47366168 |
| | Effect of sildenafil citrate on penile weight and physiology of cavernous smooth muscle in a post-radical prostatectomy model of erectile dysfunction in rats. | Q47394896 |
| | Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy | Q47446819 |
| | Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. | Q47774035 |
| | Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence | Q47906440 |
| | A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. | Q50917943 |
| | How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center. | Q51100161 |
| | Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. | Q51370043 |
| | Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. | Q51400506 |
| | Anatomic grading of nerve sparing during robot-assisted radical prostatectomy. | Q51454170 |
| | Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. | Q53105384 |
| | Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. | Q53133627 |
| | Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients? | Q54374114 |
| | Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. | Q54784574 |
| | The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary | Q59563285 |
| | ORIGINAL RESEARCH—BASIC SCIENCE: Effect of Chronic Tadalafil Administration on Penile Hypoxia Induced by Cavernous Neurotomy in the Rat | Q60673583 |
| | Impotence following radical prostatectomy: insight into etiology and prevention | Q70457087 |
| | Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial | Q73708969 |
| | The effect of hyperbaric oxygen therapy on erectile function recovery in a rat cavernous nerve injury model | Q80490437 |
| | FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms | Q80604103 |
| | Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil | Q80730251 |
| | Choosing the best candidates for penile rehabilitation after bilateral nerve-sparing radical prostatectomy | Q83092975 |
| | Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? | Q83220905 |
| | Molecular mechanisms of vacuum therapy in penile rehabilitation: a novel animal study | Q84624408 |
| | Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy | Q85265680 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 110-23 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | Penile rehabilitation after radical prostatectomy: does it work? | |
| P478 | volume | 4 | |